Asia-Pacific Bladder Cancer Market Growth, Analysis Report, Share, Trends and Overview 2022-2028

Asia-Pacific bladder cancer market is estimated to grow at a CAGR of around 9.7% during the forecast period. The growing number of smokers in Asian economies is one of the major factors attributing to the increasing number of bladder cancer patients. The number of smokers is increasing substantially in the adult population of the region due to the changing lifestyle and shifting habits towards smoking and tobacco consumption. Other factors that are considered as the significant cause of bladder cancer include radiation exposure, intake, or exposure to hazardous chemicals, aging, and others. Aging is considered as the major factors leading to bladder cancer due to the weakening of immune cells against cancer tissues in the bladder. Countries of Asia-Pacific such as Japan and China are reported to the aging population rapidly. Therefore, Asia-Pacific is comparatively more prone to bladder cancer as compared to other regions.

A full report of Asia-Pacific Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-bladder-cancer-market

Asia-Pacific bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The chemotherapy is highly adopted as it kills cancer cells that are spread to other parts of the body, far from its primary tumor.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-bladder-cancer-market

The companies which are contributing to the growth of the Asia-Pacific bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Sysmex Corp., and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launches, mergers, and acquisitions, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Asia-Pacific Bladder Cancer Market- Segmentation

By Cancer type

• Transitional Cell Bladder Cancer/ Urothelial Carcinoma
• Squamous Cell Bladder Cancer
• Adenocarcinoma
• Other Rare Types (Sarcomas, Carcinoma in Situ)

By Diagnosis Method

• Cystoscopy
• Biopsy
• Urinalysis
• Urine Cytology
• Intravenous Pyelogram (Ivp)
• Other

By Therapy

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery
• Other

Asia-Pacific Bladder Cancer Market- Segment by Region

• China
• Japan
• India
• Rest of Asia-Pacific

Company Profiles

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Pfizer Inc.
• Sysmex Corp.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.